Name (Synonyms) | Correlation | |
---|---|---|
drug1011 | Group B Control Wiki | 1.00 |
drug1009 | Group A HCQ Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Patients who are severely ill with COVID-19 may benefit from receiving plasma infusions from donors who have recovered from the disease and are proven to no longer be infected. Efforts to initiate the collection and infusion of these products to high risk patients have been initiated around the world and the FDA has recently provided information about how this could be accomplished. As the Jefferson Blood Donor Center already has processes to collect, test and process blood, investigators are planning to make efforts to collect plasma for this use should it be necessary. The purpose of this study is to describe the process for identifying and collecting convalescent plasma from donors previously infected with the virus. The research portion on top of this standard blood product collection will the process of identification of subjects and processes by which blood products are processed in this special population. This protocol does not involve the administration of blood products to patients with COVID-19 infection.
Description: # of individuals screened eligible
Measure: Number of patients who screen eligible for donation Time: 1 yearDescription: # of patients who consent to donation
Measure: Number of patients who consent to plasma donation Time: 1 yearDescription: # of plasma donations received
Measure: Number of plasma donations received Time: 1 yearDescription: Side effects or adverse events related to plasma donation
Measure: Safety of donation procedures Time: 1 year